Search Results - "Bociek, Robert G"

Hedgehog-Induced Survival of B-Cell Chronic Lymphocytic Leukemia Cells in a Stromal Cell Microenvironment: A Potential New Therapeutic Target by Hegde, Ganapati V, Peterson, Katie J, Emanuel, Katy, Mittal, Amit K, Joshi, Avadhut D, Dickinson, John D, Kollessery, Gayathri J, Bociek, Robert G, Bierman, Philip, Vose, Julie M, Weisenburger, Dennis D, Joshi, Shantaram S

“…B-cell chronic lymphocytic leukemia (B-CLL) is characterized by an accumulation of neoplastic B cells due to their resistance to apoptosis and increased…”
Get full text

Rituximab Improves the Outcome of Patients with Grade 3 Follicular Lymphoma Receiving Anthracycline-based Therapy by Yuan, Ji, MD, PhD, Greiner, Timothy C., MD, Fu, Kai, MD, PhD, Smith, Lynette M., PhD, Aoun, Patricia, MD, Chan, Wing C., MD, Bierman, Philip J., MD, Bociek, Robert G., MD, Vose, Julie M., MD, MBA, Armitage, James O., MD, Weisenburger, Dennis D., MD

“…Abstract Background The addition of rituximab to chemotherapy has improved the outcome of patients with follicular lymphoma (FL). However, data on grade 3 FL…”
Get full text

Outcomes of Richter’s transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database by Elnair, Radowan, Ellithi, Moataz, Kallam, Avyakta, Shostrom, Valerie, Bociek, Robert G.

“…Richter’s transformation (RT) is a rare complication arising in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and is…”
Get full text

MYC and BCL2 protein expression predicts survival in patients with diffuse large B‐cell lymphoma treated with rituximab by Perry, Anamarija M., Alvarado‐Bernal, Yuridia, Laurini, Javier A., Smith, Lynette M., Slack, Graham W., Tan, King L., Sehn, Laurie H., Fu, Kai, Aoun, Patricia, Greiner, Timothy C., Chan, Wing C., Bierman, Philip J., Bociek, Robert G., Armitage, James O., Vose, Julie M., Gascoyne, Randy D., Weisenburger, Dennis D.

“…Summary Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disease and “double‐hit” DLBCL, with both MYC and BCL2 translocations has a poor prognosis. In…”
Get full text

Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium by Vose, Julie M, Fu, Kai, Wang, Lu, Mansoor, Adnan, Stewart, Douglas, Cheng, Hongxia, Smith, Lynette, Yuan, Ji, Qureishi, Hina Naushad, Link, Brian K, Cessna, Melissa H, Barr, Paul M, Kahl, Brad S, Mckinney, Matthew S, Khan, Nadia, Advani, Ranjana H, Martin, Peter, Goy, Andre H, Phillips, Tycel J, Mehta, Amitkumar, Kamdar, Manali, Crump, Michael, Pro, Barbara, Flowers, Christopher R, Jacobson, Caron A, Smith, Sonali M, Stephens, Deborah M, Bachanova, Veronika, Jin, Zhaohui, Wu, Shishou, Hernandez-Ilizaliturri, Francisco, Torka, Pallawi, Anampa-Guzmán, Andrea, Kashef, Farshid, Li, Xing, Sharma, Sunandini, Greiner, Timothy C, Armitage, James O, Lunning, Matthew, Weisenburger, Dennis D, Bociek, Robert G, Iqbal, Javeed, Yu, Guohua, Bi, Chengfeng

“…Patients with mantle cell lymphoma (MCL) exhibit a wide variation in clinical presentation and outcome. However, the commonly used prognostic models are…”
Get full text

Follicular large cleaved cell (centrocytic) lymphoma: an unrecognized variant of follicular lymphoma by El Behery, Radwa, Laurini, Javier A., Weisenburger, Dennis D., Smith, Lynette M., Dave, Bhavana J., Yuan, Jane, Fu, Kai, Chan, Wing C., Nathwani, Bharat N., Bierman, Phillip J., Bociek, Robert G., Vose, Julie M., Armitage, James O., Greiner, Timothy C., Aoun, Patricia

“…The World Health Organization classification of lymphoma recommends the subdivision of follicular lymphoma (FL) into 3 grades (FL1-3) based on the average…”
Get full text

Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1 by Gilling, Christine E., Mittal, Amit K., Chaturvedi, Nagendra K., Iqbal, Javeed, Aoun, Patricia, Bierman, Philip J., Bociek, Robert G., Weisenburger, Dennis D., Joshi, Shantaram S.

“…Summary Emerging evidence indicates that the tumour microenvironment (TME) regulates the behaviour of chronic lymphocytic leukaemia (CLL). However, the precise…”
Get full text

The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma by Mitrovic, Zdravko, Bast, Martin, Bierman, Philip J., Bociek, Robert G., Vose, Julie M., Chan, Wing C., Armitage, James O.

Get full text

Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome by Caponetti, Gabriel C, Dave, Bhavana J, Perry, Anamarija M, Smith, Lynette M, Jain, Smrati, Meyer, Paul N, Bast, Martin, Bierman, Philip J, Bociek, Robert G, Vose, Julie M, Armitage, James O, Aoun, Patricia, Fu, Kai, Greiner, Timothy C, Chan, Wing C, Sanger, Warren G, Weisenburger, Dennis D

“…In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients…”
Get full text

Late relapse in patients with diffuse large B‐cell lymphoma by Vose, Julie M., Weisenburger, Dennis D., Loberiza, Fausto R., Arevalo, Alejandro, Bast, Martin, Armitage, Joel, Bierman, Philip J., Bociek, Robert G., Armitage, James O.

“…Summary The outcomes for 162 patients with diffuse large B‐cell lymphoma treated with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)‐like…”
Get full text

A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival by Hans, Christine P., Weisenburger, Dennis D., Vose, Julie M., Hock, Lynette M., Lynch, James C., Aoun, Patricia, Greiner, Timothy C., Chan, Wing C., Bociek, Robert G., Bierman, Philip J., Armitage, James O.

“…Grade 3 follicular lymphoma (FL3) is thought to have an aggressive clinical course. On the basis of possible biologic differences, the new World Health…”
Get full text

Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities by Mittal, Amit, Hegde, Ganapati, Aoun, Patricia, Bociek, Robert, Dave, Bhavana, Joshi, Avadhut, Sanger, Warren, Weisenburger, Dennis, Joshi, Shantaram

“…In B-cell chronic lymphocytic leukemia (CLL), Rai stage, immunoglobulin gene mutational status, chromosomal abnormalities, CD38 and ZAP-70 expression were used…”
Get full text

Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma by Vose, Julie M, Bierman, Philip J, Loberiza, Fausto R, Enke, Charles, Hankins, Jordan, Bociek, Robert G, Chan, Wing C, Weisenburger, Dennis D, Armitage, James O

“…Abstract The purpose of this study was to evaluate the standard outpatient dose of 131-Iodine tositumomab (75 cGy) combined with high-dose carmustine,…”
Get full text

Outcomes of Patients with Central Nervous System Complications After Allogeneic Hematopoietic Stem Cell Transplantation by Akhtari, Mojtaba, Jasem, Jagar, Armitage, James O, Balasetti, Vamshi K.S, Bierman, Philip J, Faber, Edward A, Fayad, Pierre, Hadi, Abdul, Loberiza, Fausto Rodriguez, Maness, Lori, Rosales, Armando D.A, Vose, Julie M, Bociek, Robert G

Get full text

MYC and BCL 2 protein expression predicts survival in patients with diffuse large B ‐cell lymphoma treated with rituximab by Perry, Anamarija M., Alvarado‐Bernal, Yuridia, Laurini, Javier A., Smith, Lynette M., Slack, Graham W., Tan, King L., Sehn, Laurie H., Fu, Kai, Aoun, Patricia, Greiner, Timothy C., Chan, Wing C., Bierman, Philip J., Bociek, Robert G., Armitage, James O., Vose, Julie M., Gascoyne, Randy D., Weisenburger, Dennis D.

“…Summary Diffuse large B ‐cell lymphoma ( DLBCL ) is a heterogeneous disease and “double‐hit” DLBCL , with both MYC and BCL 2 translocations has a poor…”
Get full text

Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion by Joshi, Avadhut D, Dickinson, John D, Hegde, Ganapati V, Sanger, Warren G, Armitage, James O, Bierman, Philip J, Bociek, Robert G, Devetten, Marcel P, Vose, Julie M, Joshi, Shantaram S

“…Abstract B-cell chronic lymphocytic leukemia (B-CLL) is the most common B-cell leukemia among older populations in Western countries. The clinical course of…”
Get full text

GLI1 Transcription Factor: A Potential Therapeutic Target in B-CLL by Hegde, Ganapati V., Peterson, Katie J., Emanuel, Katy, Mittal, Amit K., Bociek, Robert G., Weisenburger, Dennis D., Joshi, Shantaram S.

“…B-cell Chronic Lymphocytic Leukemia (B-CLL) is characterized by accumulation of clonal lymphocytes resistant to apoptosis. Therefore, identification of…”
Get full text

Mechanism of Alemtuzumab Depletion of T Cells in Stem Cell Products by Gulen, Dumrul, Bociek, Robert G., Coskun, Ugur, Devetten, Marcel P., Talmadge, James E.

“…Alemtuzumab (a humanized murine monoclonal antibody [MAb] against CD52) is an effective drug for in vitro T cell purging of allogeneic stem cell products when…”
Get full text

Effect of T Cell Recovery on Overall Survival (OS) Following Pentostatin Conditioning for Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) by Talmadge, James E., Coskun, Ugur, Maas, Sarah, Turken, Orhan, Pavletic, Ziviko S., Kuszynski, Charles A., Devetten, Marcel, Schafer, Laura R., Zobel, Lori, Bociek, Robert G.

“…NST provides graft-versus-leukemia (GVL) activity with reduced regimen related toxicity. We used a conditioning regimen consisting of Pentostatin 4 mg/m2 daily…”
Get full text

Relapse from Complete Remission More Than 5 Years after Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Relapse Histology Most Commonly DLBCL with a Germinal Center B-Cell (GCB) Phenotype by Vose, Julie M., Chan, John C., Bierman, Philip J., Arevalo, Alejandro, Loberiza, Fausto, Fu, Kai, Weisenburger, Dennis, Bociek, Robert G., Bast, Martin, Armitage, James O.

“…Although many patients are successfully treated for DLBCL, relapses can occur especially in the higher risk patients. Relapses in successfully treated DLBCL…”
Get full text